IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. will host a conference call today, November 18, 2004 at 10:30 AM eastern time.
Vicente Anido, Jr., Ph.D., ISTA's Chief Executive Officer will discuss the Company's recently announced license agreement for ecabet sodium. As announced earlier today, ISTA has licensed from Senju Pharmaceuticals Co., Ltd. exclusive U.S. marketing rights for ecabet sodium, a prescription eye drop for the treatment of dry eye syndrome (keratoconjunctivitis sicca, or KCS).
In addition, Dr. Anido will provide an update on the commercial, regulatory and clinical progress of ISTA's other marketed and development-stage products, including Vitrase(R), Istalol(TM) and Xibrom(TM).
Conference call and webcast
To access the live conference call, U.S. and Canadian participants may dial (800) 817-4887; international participants may dial (913) 981-4913. To access the 24-hour audio replay, U.S. and Canadian participants may dial (888) 203-1112; international participants may dial (719) 457-0820. The access code for the call is 859860. This conference call will also be webcast live and archived on ISTA's website at http://www.istavision.com/ for 30 days.
ISTA is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products. ISTA's products and product candidates seek to address serious diseases and conditions of the eye such as dry eye, vitreous hemorrhage, diabetic retinopathy, hyphema, glaucoma, ocular pain and inflammation. Building on this pipeline, ISTA's goal is to continue its growth as a specialty pharmaceutical company by acquiring complementary products, either already marketed or in late-stage development. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com/.
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. ISTA disclaims any intent or obligation to update any forward-looking statements. Such statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the inherent uncertainty associated with financial projections; and such risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2003 and its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2004, June 30, 2004 and September 30, 2004.
ISTA Pharmaceuticals, Inc.
CONTACT: Vince Anido, +1-949-788-5311, email@example.com, or LaurenSilvernail, +1-949-788-5302, firstname.lastname@example.org, both of ISTAPharmaceuticals; or Media: Justin Jackson, email@example.com, or Investors:Lisa Burns or Aline Schimmel, firstname.lastname@example.org, +1-212-213-0006, all ofBurns McClellan, for ISTA Pharmaceuticals